Informations sur le produit
CFMTI is a novel allosteric modulator of metabotropic glutamate receptors (mGluRs). It is being developed for the treatment of female infertility. The drug has been shown to be orally bioavailable in rats and to increase the responsiveness of ovarian follicles to gonadotropins. CFMTI may also have therapeutic potential in the treatment of depression, anxiety disorders, Parkinson's disease, and schizophrenia.